Acadia Pharmaceuticals Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$1.07B
Cost of Revenue
$89M
Gross Profit
—
R&D
$329M
SG&A
$549M
D&A
$871K
Operating Income
$105M
EBITDA
$106M
Interest Expense
$32M
Other Income/Expense
$66M
Pretax Income
$139M
Tax Provision
$-252M
Net Income
$391M
Gross Margin
—
Operating Margin
9.8%
Net Margin
36.5%
Effective Tax Rate
-181.5%
Deferred Tax Assets
$39M
Deferred Tax Liabilities
$11M
DTA Valuation Allowance
$115M
Tax Credit Carryforwards
$52M
NOL Carryforwards
$77M
ETR (Continuing Operations)
-181.5%
ETR Federal Statutory
21.1%
ETR State + Local (pp)
-17.9%
Operating Lease Cost
$15M
Revenue YoY Variation
11.9%
Income YoY Variation
-54.6%